NEUROKIN Strengthens its Board of Directors and Scientific Committee

MARSEILLE, France--(BUSINESS WIRE)-- The biotechnology company NEUROKIN, dedicated to the development of neuroprotective drugs to treat acute neurological diseases, announces today the appointment of Mr. Bernard Reculeau as a new member of the Board of Directors, and the arrival of Mr. Jesús Benavides within the company’s Scientific Committee.

Bernard has over 25 years of experience in leadership positions in the pharmaceutical industry. At Rhone Poulenc since 1984, he served as General Manager of Pharmuka (launch of Lovenox in France), Senior Vice President Worldwide Industrial Operations, Senior Vice President France and Benelux and finally, Senior Vice President and General manager of Rhone-Poulenc Rorer International. Bernard continued his career at Aventis, where he served as Senior Vice President of pharmaceutical operations until 2005. Bernard also has a good knowledge of biotechnology companies, since he led CISBIO from 2006 to late 2009 and is still, since 2005, a member of the Board of Directors of the Canadian company Theratechnologies.

Bernard graduated from the Institut d’Etudes Politiques de Paris (1974) and the Ecole Nationale d’Administration (1977).

Jesus’ scientific expertise is based on nearly 30 years of experience in R&D within the pharmaceutical industry. He headed until 2000, the department of neurobiology of Sanofi-Synthelabo Research Unit. Between 2000 and 2010 he held various management positions in R&D at Aventis and Sanofi-Aventis. He was Vice President and Head of the Neurodegenerative Diseases Research of Aventis before becoming Vice President and Global Head of Research in Neurology. Nowadays, Jesus also teaches translational neurology in France and Spain; he is a Consultant in pharmaceutical R&D for Pharmaceutical companies and Biotech companies in the field of central nervous system.

Jesús holds a Ph.D. in Biochemistry (Molecular Biology center - University of Madrid)

Jérôme BECQUART, CEO of NEUROKIN declared: « I am very pleased that Bernard joins our Board. Neurokin will take advantage of his valuable and worldwide experience in both pharmaceutical and biotechnology industry. His perfect comprehension of the sector and its strategic issues will strengthen our corporate strategy allowing us to make the best use of the results obtained by the Company. »

Serge TIMSIT, Founder and Scientific adviser of NEUROKIN added: «The industrial experience brought by Jesus in the fields of Central Nervous System (CNS) and neuropharmacology will be very useful for the development of our molecules and also in our relationships with the targeted industries.»

About NEUROKIN
Founded in 2003 by neuroscientists, doctors and based on scientific research coming from INSERM and CNRS, NEUROKIN is a biotechnology company developing neuroprotective agents to treat acute neurological diseases. These are serious diseases such as stroke, Traumatic Brain Injury (TBI) and some forms of epilepsy, which destroy permanently brain cells within a few days and for which there is no existing effective treatment.
NEUROKIN develops its expertise on the NK molecules, which are capable of protecting brain cells, particularly neurons, immediately after the occurrence of an accident or a traumatic brain injury. NK-102 is the first drug candidate from this family on which NEUROKIN focuses its development efforts. The company has exclusive worldwide licenses for the use of NK molecules and has been granted with a specific patent for NK-102 issued by the EPO.
For more information please visit: http://www.neurokin.com



CONTACT:

Jérôme Becquart – CEO
(+33) (0) 1 47 01 31 33
[email protected]
or
Milestones – Press Relations
Bruno Arabian / Jacques-Olivier Costa
(+33) (0)1 75 44 87 40/42
[email protected]
[email protected]

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Technology  Networks  Health  Biotechnology  Clinical Trials  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.